B001

BIOLOGICAL2 trials

Sponsors

Shanghai Pharmaceuticals Holding Co., Ltd, Shanghai Jiaolian Drug Research and Development Co., Ltd

Conditions

CD20 Positive B Cell Non-Hodgkin's LymphomaNeuromyelitis Optica Spectrum Disorders

Phase 1

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

CompletedNCT03332121

Shanghai Pharmaceuticals Holding Co., LtdCD20 Positive B Cell Non-Hodgkin's Lymphoma

Start: 2018-03-22End: 2021-02-28Updated: 2021-11-15

Phase 2

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

RecruitingNCT06413654

Shanghai Jiaolian Drug Research and Development Co., LtdNeuromyelitis Optica Spectrum Disorders

Start: 2024-07-17End: 2029-02-28Target: 132Updated: 2026-05-05